Paradoxical reaction under dupilumab triggered by occasional ketoprofen intake
Dupilumab, a monoclonal antibody targeting the IL-4/13 signaling pathway, effectively treats moderate-to-severe atopic dermatitis (AD). Common side effects include injection site reactions, conjunctivitis, and respiratory infections. We report the case of a 28-year-old woman with severe AD involving the periocular and chin regions, genital areas, arms, and legs (Eczema Area and Severity Index [EASI]: 24, itch Visual Analog Scale [VAS]: 8) who showed significant improvement after initiating dupilumab therapy. However, following ketoprofen intake for headache relief, she developed a lupus-like erythematous maculopapular rash on the periocular and malar regions. Immunological tests (antinuclear antibody [ANA] and extractable nuclear antigen [ENA]) and photopatch testing ruled out autoimmune or allergic causes. Dupilumab was stopped, and treatment with oral prednisone and cetirizine led to complete resolution. This case highlights a potential drug interaction between dupilumab and ketoprofen, emphasizing the need for awareness of paradoxical facial erythema reactions in patients undergoing dupilumab therapy.
Authors
- Sanja Javor (ORCID: https://orcid.org/0000-0003-2614-0207)
- Cesare Massone (ORCID: https://orcid.org/0000-0002-0996-643X)
- Filippo Chersi (ORCID: https://orcid.org/0009-0007-0164-9863)
- Elia Sala
- Rosella Gallo (ORCID: https://orcid.org/0000-0002-1735-4425)
Institutions
- University of Trieste (IT)
- Martin University (US)
- Ente Ospedaliero Ospedali Galliera (IT)
- Ospedale Policlinico San Martino (IT)
Publication Details
- Journal
- Dermatology Reports
- Published
- 2025-02-28
- DOI
- https://doi.org/10.4081/dr.2025.10214
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00